This web site is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

Symmetrel

Endo International plc

Drug Names(s): Amantadine

Description: Symmetrel is an anti-viral drug that was later found to have benefit in patients with Parkinson's disease. The mechanism by which Symmetrel exerts its antiviral activity is not clearly understood. It appears to mainly prevent the release of infectious viral nucleic acid into the host cell by interfering with the function of the transmembrane domain of the viral M2 protein. In certain cases Symmetrel is also known to prevent virus assembly during virus replication. It does not appear to interfere with the immunogenicity of inactivated influenza A virus vaccine. Symmetrel inhibits the replication of influenza A virus isolates from each of the subtypes, i.e., H1N1, H2N2 and H3N2. It has very little or no activity against influenza B virus isolates.

The mechanism of action of Symmetrel in the treatment of Parkinson's Disease and drug-induced extrapyramidal reactions is not known. Data from earlier animal studies suggest that it may have direct and indirect effects on dopamine neurons. More recent studies have demonstrated that Symmetrel is a weak, non-competitive NMDA receptor antagonist.


Symmetrel News


Additional information available to subscribers only:

  • Targets
  • Routes
  • Catalysts
  • Designations
  • Events

Request a Free Demo Subscriber Login Search for another drug